TSUMURA & CO. Logo

TSUMURA & CO.

A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1893, Tsumura & Co. is a leading Japanese pharmaceutical company specializing in Kampo medicine, a traditional Japanese herbal therapy. The company's primary business is the manufacture and sale of prescription and over-the-counter (OTC) Kampo formulations, which are derived from natural substances. Its product portfolio also includes other medications and consumer items such as herbal bath salts. Tsumura manages an integrated value chain, from the procurement of raw medicinal herbs to the production of finished goods. The company is guided by a philosophy of achieving “Cho-WA” (harmony) between mind and body, blending tradition with scientific innovation to contribute to individual and societal well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 07:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-08-05 07:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-07-08 07:37
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-07-01 09:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第89期(2024/04/01-2025/03/31)
Japanese 25.7 KB
2025-06-24 06:21
Annual Report
有価証券報告書-第89期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2025-06-24 06:21
Registration Form
確認書
Japanese 8.9 KB
2025-06-11 06:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-05-12 07:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.0 KB
2025-04-07 07:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-03-10 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-03-03 08:27
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.2 KB
2025-02-20 07:30
Share Issue/Capital Change
臨時報告書
Japanese 27.8 KB
2024-11-08 07:11
Interim Report
確認書
Japanese 8.9 KB
2024-11-08 07:08
Interim Report
半期報告書-第89期(2024/04/01-2025/03/31)
Japanese 242.2 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America AGIO
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.